Please use this identifier to cite or link to this item:
Scopus Web of Science® Altmetric
Type: Journal article
Title: Prognostic significance of early molecular response in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors
Author: Yeung, D.
Mauro, M.
Citation: Hematology, 2014; 2014(1):240-243
Publisher: American Society of Hematology
Issue Date: 2014
ISSN: 1520-4391
Statement of
David T. Yeung, and Michael J. Mauro
Abstract: A 55-year-old man presented with splenomegaly (10 cm below left costal margin) and leucocytosis (145 × 10(9)/L). Differential showed neutrophilia with increased basophils (2%), eosinophils (1.5%), and left shift including myeloblasts (3%). A diagnosis of chronic myeloid leukemia in chronic phase was established after marrow cytogenetics demonstrated the Philadelphia chromosome. Molecular studies showed a BCR-ABL1 qPCR result of 65% on the International Scale. Imatinib therapy at 400 mg daily was initiated due to patient preference, with achievement of complete hematological response after 4 weeks of therapy. BCR-ABL1 at 1 and 3 months after starting therapy was 37% and 13%, respectively (all reported on International Scale). Is this considered an adequate molecular response?
Keywords: Humans; Protein Kinase Inhibitors; Prognosis; Disease-Free Survival; Treatment Outcome; Middle Aged; Male; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Practice Guidelines as Topic
Rights: © 2015 by the American Society of Hematology
RMID: 0030021252
DOI: 10.1182/asheducation-2014.1.240
Appears in Collections:Medicine publications

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.